Literature DB >> 27875974

Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.

Avia Wilkerson1, Julian Kim2, Alex Y Huang3, Mei Zhang4.   

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that are preferentially expanded in cancer. They arise from myeloid progenitor cells that do not differentiate into mature dendritic cells (DCs), granulocytes, or macrophages, and are rather thought to play a pivotal role in immune escape and cancer progression. MDSCs are characterized by the ability to suppress T cell proliferation and cytotoxicity, inhibit natural killer T (NKT) cell activation, and induce the differentiation and expansion of regulatory T cells (Treg). MDSC levels have been shown to correlate negatively with prognosis and overall survival of patients with cancers of various types and stages. The role of MDSCs in cancer progression represents a promising target for effective cancer immunotherapy. In this review, we discuss the mechanisms of MDSC functions, their influence on tumor progression and metastasis, and finally focus on up to date nanoparticle approaches that target and antagonize MDSCs in tumor-bearing hosts. The development of multifunctional nanoparticle systems for effective imaging, assessment and manipulation of MDSCs will represent strategic theranostic innovations that may improve cancer staging, therapeutic outcomes, and overall patient survival. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Cancer Therapy; Glucan-Based Nanoparticle; Immunotherapy,; Myeloid Derived Suppressor Cells (MDSCs); Nanomedicine; Tumor-induced Immunezzm321990Suppression

Mesh:

Year:  2017        PMID: 27875974     DOI: 10.2174/1568026617666161122121412

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  5 in total

1.  Cargo-free immunomodulatory nanoparticles combined with anti-PD-1 antibody for treating metastatic breast cancer.

Authors:  Yining Zhang; Kevin R Hughes; Ravi M Raghani; Jeffrey Ma; Sophia Orbach; Jacqueline S Jeruss; Lonnie D Shea
Journal:  Biomaterials       Date:  2021-01-08       Impact factor: 12.479

Review 2.  New opportunities for nanoparticles in cancer immunotherapy.

Authors:  Wooram Park; Young-Jae Heo; Dong Keun Han
Journal:  Biomater Res       Date:  2018-09-26

3.  Human liver stem cells attenuate concanavalin A-induced acute liver injury by modulating myeloid-derived suppressor cells and CD4+ T cells in mice.

Authors:  Yanzhen Bi; Jiannan Li; Yonghong Yang; Quanyi Wang; Quanquan Wang; Xiaobei Zhang; Guanjun Dong; Yibo Wang; Zhongping Duan; Zhenfeng Shu; Tongjun Liu; Yu Chen; Kai Zhang; Feng Hong
Journal:  Stem Cell Res Ther       Date:  2019-01-11       Impact factor: 6.832

Review 4.  The Role of Invariant NKT in Autoimmune Liver Disease: Can Vitamin D Act as an Immunomodulator?

Authors:  Daniel S Smyk; Athanasios Mavropoulos; Giorgina Mieli-Vergani; Diego Vergani; Marco Lenzi; Dimitrios P Bogdanos
Journal:  Can J Gastroenterol Hepatol       Date:  2018-06-26

Review 5.  Emerging Prospects for Nanoparticle-Enabled Cancer Immunotherapy.

Authors:  Manal Ali Buabeid; El-Shaimaa A Arafa; Ghulam Murtaza
Journal:  J Immunol Res       Date:  2020-01-03       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.